Presentation is loading. Please wait.

Presentation is loading. Please wait.

0 SK Life Science Introduction 2008. June. 1 SK holdings SK Chemicals Life Science Biz Life Science Division Revenue: $ 848 MM Employee > 300 Revenue:

Similar presentations


Presentation on theme: "0 SK Life Science Introduction 2008. June. 1 SK holdings SK Chemicals Life Science Biz Life Science Division Revenue: $ 848 MM Employee > 300 Revenue:"— Presentation transcript:

1 0 SK Life Science Introduction June

2 1 SK holdings SK Chemicals Life Science Biz Life Science Division Revenue: $ 848 MM Employee > 300 Revenue: $ 1.2 B. Employee > 1,150 Life Science Business is outset for the growth drive in the future Life Science in SK Group SK Group 1) E&P: Exploration & Production Holding company in SK Croup Fine Chemicals, Life Science Fine Chemicals, Life Science New Drug Development Custom Manufacturing Service New Drug Development Custom Manufacturing Service Drug development & Marketing (Korean and Asian Market) Drug development & Marketing (Korean and Asian Market)

3 2 As of July 1 st 2007, SK Corporation was divided into two companies, SK Energy and SK Holdings Ltd, and Life Science biz becomes a part of SK Holdings Previous Structure New Structure SK Corporation had various operating divisions and held many subsidiary companies Reorganize as a holding company and 8 operating companies SK Life Science stays with holding company as one operating division SK Corp. SK Telecom SK Networks Other Subsidiaries SK Holdings SK Telecom SK Networks Other Subsidiaries Purpose of Reorganization Maximizing Management Efficiency Enhancing Overall Shareholder Value Solidifying Corporate Governance Resolving the Issue of Under-valuation SK Energy Life Science Oil Refinery E&P Lubri- cants Chemicals Life Science SK Life Science

4 3 SK Life Science Biz. Organization * CMS: Custom Manufacturing Service Discovery Lab. Drug Preclinical Research Lab. R&D Planning Team New Jersey R&D Center Shanghai R&D Center Life Science Strategy Team Process R&D Lab. CMS Production Team Marketing Team(New Jersey) Seoul, Korea Daejeon, Korea Shanghai, China New Jersey, USA CMS Business (CMS 사업부 ) Drug Development Center ( 신약개발사업부 )

5 Drug Development Center

6 5 KOREA [Seoul] Strategic Planning Licensing Out [LSRDP 1) ] R&D Planning Licensing In Drug Discovery Early Preclinical Studies Formulation Studies Intellectual Properties USA [New Jersey] Advanced Preclinical Studies Clinical Studies in USA Regulatory Affairs in USA CHINA [Shanghai] Drug discovery Market research in China 1) LSRDP: Life Science R&D Park Drug Development Center Role & Responsibility

7 Start Pharmaceutical research in New Jersey, US and Daejeon, Korea focusing on CNS area YKP10A IND Approval for YKP10A, an antidepressant, from U.S. FDA YKP509 IND Approval for YKP509, an anticonvulsant, from U.S. FDA Licensing Out J&J ( to J&J (YKP10A) Licensing Out to J&J to J&J (YKP509) YKP1358 IND Approval for YKP1358, an Antipsychotic, from U.S. FDA YKP3089 IND Approval for YKP3089, an anxiolytic, from U.S. FDA (currently at POC entering) Establish Shanghai Drug Dev. Center 2002 The first Korean company to obtain IND approval from U.S. FDA Licensing Out to Johnson & Johnson (CNS field) Developing globally competitive new drug pipeline 2007 New IND expected History

8 7 Neuropathic Pain Parkinson MetabolicdiseasesMetabolicdiseases CNSCNS Obesity Diabetes Epilepsy Depression Schizophrenia DDSDDS Transdermal Controlled release Intranasal Technology R&D Areas Successful track records in CNS drug discovery Epilepsy, Depression, Schizophrenia, Neuropathic pain and Parkinson etc. Expansion toward Metabolic diseases Obesity, Diabetes and Osteoporosis CVCV Restenosis

9 8 DDS Pipeline Status Metabolic CV CNS By J&J Planning IND & Phase I in 2008 DiscoveryLeadPreclinicalPhase IPhase IIPhase III Partnering Alliance - Clinical Study expected in May, 2008 Narcolepsy, Drug addiction (Ready to IND) on-going Preclinical studies w/ active enantiomer (YKP1447)

10 CMS Business

11 10 KOREA [Seoul] Planning [LSRDP 1) ] Production Process Development QC/QA USA [New Jersey] Marketing Market Research Customer Relationship CHINA [Shanghai] Process Development Biz Development Raw Material Purchasing CMS Business Role & Responsibility 1) LSRDP: Life Science R&D Park

12 11 1)GMP (Good Manufacturing Practice) Overview Customers Global Major Pharmaceutical Companies Pfizer, Roche, Bristol-Meyers-Squibb, Schering Plough, Novartis, GSK, J&J, etc. Technology Catalytic Processes, Continuous Reaction Technologies Enzymatic technology Conventional Organic Synthesis Products & Services GMP Intermediates and API (End of 2007) Process development and DMF support for customers –Catalytic and Continuous Processes –Co-Work and DMF support History & Location Operation since 2000 based on R&D capabilities Production Plants and R&D in Daejeon, Korea Marketing in NJ, USA SK CMS provides custom manufacturing service to the global major pharma companies based on the innovative technological and production capabilities with a cGMP complied quality system

13 12 Quality System Plant Operation based upon cGMP & ICH Q7A Quality Management System Material Control System Facilities & Equipment System Production & In-Process Control System Laboratory Control System Quality Assurance based on Quality Management Systems ’98 ~’01 GSK ’02 ~’03 Roche, Novartis, Pfizer ’04 ~’05 Pfizer, GSK, BMS, Lonza ’06 Pfizer, BMS (Approved for cGMP Intermediate Production) Current Preparation of API Production and DMF Filing for New Drug Audits and Approval by Many Customers

14 13 `08 년 하반기 신입 사원 채용 모집분야 주요업무 주요업무모집인원 Process Chemist 유기합성 기술을 활용한 신약 후보물질 및 관련 중간체 제조 공정 개발 연구 0명0명 Process Engineer 신규 촉매 개발, 신규 연속공정 개발 업무 0명0명

15 Thank you


Download ppt "0 SK Life Science Introduction 2008. June. 1 SK holdings SK Chemicals Life Science Biz Life Science Division Revenue: $ 848 MM Employee > 300 Revenue:"

Similar presentations


Ads by Google